董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Bridget A. Ross Independent Director 61 24.10万美元 未持股 2026-04-01
Martha Shadan Independent Director 70 23.55万美元 未持股 2026-04-01
George W. LeMaitre Director,Chairman of the Board and Chief Executive Officer 61 378.10万美元 未持股 2026-04-01
David B. Roberts Director and President 62 127.33万美元 未持股 2026-04-01
Joseph P. Pellegrino, Jr. Director 61 55.78万美元 未持股 2026-04-01
Lawrence J. Jasinski Independent Director 68 25.90万美元 未持股 2026-04-01
John J. O'Connor Independent Director 78 25.45万美元 未持股 2026-04-01
John A. Roush Independent Director 61 24.55万美元 未持股 2026-04-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Dorian LeBlanc Chief Financial Officer 51 107.78万美元 未持股 2026-04-01
Dorian LeBlanc Chief Financial Officer 51 未披露 未持股 2026-04-01
George W. LeMaitre Director,Chairman of the Board and Chief Executive Officer 61 378.10万美元 未持股 2026-04-01
Trent G. Kamke Senior Vice President, Operations 55 95.93万美元 未持股 2026-04-01

董事简历

中英对照 |  中文 |  英文
Bridget A. Ross

Bridget A. Ross自2017年2月以来一直在公司任职,担任全球医疗集团总裁。她还是执行管理委员会的成员。 Ross女士负责全球医疗集团的整体领导,包括战略方向,管理和业务绩效。通过与团队合作,她负责该集团的销售,市场营销,运营,业务发展和技术解决方案。罗斯女士曾担任强生医疗设备集团北美商业运营副总裁。罗斯(Ross)女士在强生(Johnson&Johnson)的28年职业生涯中,曾担任强生医疗设备公司Acclarent,Inc.的全球总裁和Ethicon的妇女健康与泌尿科全球总裁。 Ross女士曾在杜克大学Fuqua商学院的卫生部门咨询委员会任职,并代表强生公司担任Inspire Medical Systems,Inc.执行董事会成员。


Bridget A. Ross has served as CEO of ChroniSense Medical, Ltd., developer of a wearable medical-grade disease management device, and since January 2020 she has also served as advisor to Picomole, Inc., a medical technology company focused on developing a breath test for lung cancer. Additionally, Ms. Ross serves on the steering committee of MassMedic and as the Executive in Residence for the association's IGNITE accelerator program. From 2017 to 2018 Ms. Ross was President of the Global Medical Group and member of the Executive Management team at Henry Schein, Inc., an international medical and dental product distributor/solutions provider. From 1988 to 2017 she held numerous senior leadership roles at Johnson & Johnson, Inc., including, most recently VP of Commercial Operations for Medical Devices, North America. Ms. Ross holds a Bachelor of Commerce degree from the University of Alberta.
Bridget A. Ross自2017年2月以来一直在公司任职,担任全球医疗集团总裁。她还是执行管理委员会的成员。 Ross女士负责全球医疗集团的整体领导,包括战略方向,管理和业务绩效。通过与团队合作,她负责该集团的销售,市场营销,运营,业务发展和技术解决方案。罗斯女士曾担任强生医疗设备集团北美商业运营副总裁。罗斯(Ross)女士在强生(Johnson&Johnson)的28年职业生涯中,曾担任强生医疗设备公司Acclarent,Inc.的全球总裁和Ethicon的妇女健康与泌尿科全球总裁。 Ross女士曾在杜克大学Fuqua商学院的卫生部门咨询委员会任职,并代表强生公司担任Inspire Medical Systems,Inc.执行董事会成员。
Bridget A. Ross has served as CEO of ChroniSense Medical, Ltd., developer of a wearable medical-grade disease management device, and since January 2020 she has also served as advisor to Picomole, Inc., a medical technology company focused on developing a breath test for lung cancer. Additionally, Ms. Ross serves on the steering committee of MassMedic and as the Executive in Residence for the association's IGNITE accelerator program. From 2017 to 2018 Ms. Ross was President of the Global Medical Group and member of the Executive Management team at Henry Schein, Inc., an international medical and dental product distributor/solutions provider. From 1988 to 2017 she held numerous senior leadership roles at Johnson & Johnson, Inc., including, most recently VP of Commercial Operations for Medical Devices, North America. Ms. Ross holds a Bachelor of Commerce degree from the University of Alberta.
Martha Shadan

Martha Shadan自2022年9月起担任Lemaitre Vascular, Inc.董事会成员。沙丹女士在2019年至2022年期间担任Miach Orthopaedics,Inc.的总裁兼首席执行官。2018年至2019年,Shadan女士在施乐辉 PLC担任全球营销副总裁,此前该公司收购了Rotation Medical,并于2013年至2018年担任该公司总裁兼首席执行官。在加入Rotation Medical之前,2011年至2013年,她在齐默巴奥米特控担任创伤部门总裁,2007年至2011年,她在Covidien担任副总裁/血管疗法总经理以及生物外科和运动外科副总裁/总经理。此前,她还曾在百时美施贵宝公司和默沙东密理博任职。沙丹女士自2017年起担任先进医学技术协会(AdvaMed)的董事会成员。她是AdvaMed I & D倡议AdvaMed Advance的前任主席。她还在CVRx, Inc.(纳斯达克:CVRX)、S2N Health和Medartis Holding AG的董事会任职。Shadan女士是BrilliantStrings Therapeutics的董事会主席,这是一家早期初创公司,专注于治疗软组织损伤。Shadan女士拥有东北大学工商管理硕士学位、密歇根州立大学生物学理学硕士学位和新罕布什尔大学生物学理学学士学位。


Martha Shadan has served as a member of Lemaitre Vascular, Inc. Board of Directors since September 2022. Ms. Shadan was the president and chief executive officer at Miach Orthopaedics, Inc. from 2019 to 2022. From 2018 to 2019, Ms. Shadan served as global vice president of marketing at Smith & Nephew plc, following its acquisition of Rotation Medical, where she was president and chief executive officer from 2013 to 2018. Prior to joining Rotation Medical, from 2011 to 2013, she was the president of the trauma division at Zimmer Biomet, and from 2007 to 2011, she served at Covidien as vice president/general manager of vascular therapies and vice president/general manager biosurgery and sports surgery. She also previously held positions at Bristol Myers Squibb Co. and Merck Millipore. Ms. Shadan has served on the board of Advanced Medical Technology Association (AdvaMed) since 2017. She is the past chair of the AdvaMed I&D initiative, AdvaMed Advance. She also serves on the boards of CVRx, Inc. (Nasdaq: CVRX), S2N Health and Medartis Holding AG. Ms. Shadan is the chair of the board for BrilliantStrings Therapeutics, an early stage start up focused on healing soft tissue injuries. Ms. Shadan has a Master of Business Administration from Northeastern University, a Master of Science in Biology from Michigan State University, and a Bachelor of Science in Biology from the University of New Hampshire.
Martha Shadan自2022年9月起担任Lemaitre Vascular, Inc.董事会成员。沙丹女士在2019年至2022年期间担任Miach Orthopaedics,Inc.的总裁兼首席执行官。2018年至2019年,Shadan女士在施乐辉 PLC担任全球营销副总裁,此前该公司收购了Rotation Medical,并于2013年至2018年担任该公司总裁兼首席执行官。在加入Rotation Medical之前,2011年至2013年,她在齐默巴奥米特控担任创伤部门总裁,2007年至2011年,她在Covidien担任副总裁/血管疗法总经理以及生物外科和运动外科副总裁/总经理。此前,她还曾在百时美施贵宝公司和默沙东密理博任职。沙丹女士自2017年起担任先进医学技术协会(AdvaMed)的董事会成员。她是AdvaMed I & D倡议AdvaMed Advance的前任主席。她还在CVRx, Inc.(纳斯达克:CVRX)、S2N Health和Medartis Holding AG的董事会任职。Shadan女士是BrilliantStrings Therapeutics的董事会主席,这是一家早期初创公司,专注于治疗软组织损伤。Shadan女士拥有东北大学工商管理硕士学位、密歇根州立大学生物学理学硕士学位和新罕布什尔大学生物学理学学士学位。
Martha Shadan has served as a member of Lemaitre Vascular, Inc. Board of Directors since September 2022. Ms. Shadan was the president and chief executive officer at Miach Orthopaedics, Inc. from 2019 to 2022. From 2018 to 2019, Ms. Shadan served as global vice president of marketing at Smith & Nephew plc, following its acquisition of Rotation Medical, where she was president and chief executive officer from 2013 to 2018. Prior to joining Rotation Medical, from 2011 to 2013, she was the president of the trauma division at Zimmer Biomet, and from 2007 to 2011, she served at Covidien as vice president/general manager of vascular therapies and vice president/general manager biosurgery and sports surgery. She also previously held positions at Bristol Myers Squibb Co. and Merck Millipore. Ms. Shadan has served on the board of Advanced Medical Technology Association (AdvaMed) since 2017. She is the past chair of the AdvaMed I&D initiative, AdvaMed Advance. She also serves on the boards of CVRx, Inc. (Nasdaq: CVRX), S2N Health and Medartis Holding AG. Ms. Shadan is the chair of the board for BrilliantStrings Therapeutics, an early stage start up focused on healing soft tissue injuries. Ms. Shadan has a Master of Business Administration from Northeastern University, a Master of Science in Biology from Michigan State University, and a Bachelor of Science in Biology from the University of New Hampshire.
George W. LeMaitre

George W. LeMaitre,自1992年起他曾担任首席执行官并成为董事会成员。自2004年起他担任主席。之前,他曾在雷曼兄弟(Lehman Brothers)担任投资银行分析师,McCown De Leeuw公司(McCown De Leeuw公司是融资合并公司。)担任助理,康涅狄格国家银行(Connecticut National Bank)担任信贷分析师。他获得斯坦福大学(Stanford University)的历史学学士学位和斯坦福大学商学院(the Stanford University Graduate School of Business)的工商管理硕士学位。


George W. LeMaitre has served as Lemaitre Vascular, Inc. Chief Executive Officer and as a member of Lemaitre Vascular, Inc. Board of Directors since 1992, serving as Lemaitre Vascular, Inc. Chairman since 2004. Previously, Mr. LeMaitre was an investment banking analyst at Lehman Brothers, an associate at the leveraged buyout firm McCown De Leeuw, and a credit analyst for Connecticut National Bank. Mr. LeMaitre received a Bachelor of Arts in History from Stanford University and a Master of Business Administration from the Stanford University Graduate School of Business.
George W. LeMaitre,自1992年起他曾担任首席执行官并成为董事会成员。自2004年起他担任主席。之前,他曾在雷曼兄弟(Lehman Brothers)担任投资银行分析师,McCown De Leeuw公司(McCown De Leeuw公司是融资合并公司。)担任助理,康涅狄格国家银行(Connecticut National Bank)担任信贷分析师。他获得斯坦福大学(Stanford University)的历史学学士学位和斯坦福大学商学院(the Stanford University Graduate School of Business)的工商管理硕士学位。
George W. LeMaitre has served as Lemaitre Vascular, Inc. Chief Executive Officer and as a member of Lemaitre Vascular, Inc. Board of Directors since 1992, serving as Lemaitre Vascular, Inc. Chairman since 2004. Previously, Mr. LeMaitre was an investment banking analyst at Lehman Brothers, an associate at the leveraged buyout firm McCown De Leeuw, and a credit analyst for Connecticut National Bank. Mr. LeMaitre received a Bachelor of Arts in History from Stanford University and a Master of Business Administration from the Stanford University Graduate School of Business.
David B. Roberts

David B. Roberts,自2007年以来他一直担任总裁。自2001年以来他成为董事会的成员。他担任副总裁负责业务开发。2000年-2007年他担任首席财务官。从1994年到1997年在BUCA, Inc.公司他担任过许多职位负责BUCA di Beppo餐厅的运营。最近他担任副总裁负责拓展业务。在此之前他担任财务总监职务。从1992年到1994年,他在汉考克公司(Hancock Venture Partners)担任过几个职位,最近的是助理。他获得布朗大学(Brown University)商业经济学和历史学学士学位和斯坦福大学商学院(Stanford University Graduate School of Business)的工商学硕士学位。他是Parasole Restaurant Holdings的董事。他在明尼阿波里斯市的圣保罗地区拥有几家餐厅,除此之外还有许多牛排餐厅。


David B. Roberts has served as Lemaitre Vascular, Inc. President since 2007 and as a member of Lemaitre Vascular, Inc. Board of Directors since 2001. Mr. Roberts joined Lemaitre Vascular, Inc. in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000, which position he held until 2007. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts is a director of Anteris Technologies (Nasdaq: AVR) where he serves as chair of the audit committee. He is also a director of Lexington Medical, Inc. and of Parasole Restaurant Holdings, Inc.
David B. Roberts,自2007年以来他一直担任总裁。自2001年以来他成为董事会的成员。他担任副总裁负责业务开发。2000年-2007年他担任首席财务官。从1994年到1997年在BUCA, Inc.公司他担任过许多职位负责BUCA di Beppo餐厅的运营。最近他担任副总裁负责拓展业务。在此之前他担任财务总监职务。从1992年到1994年,他在汉考克公司(Hancock Venture Partners)担任过几个职位,最近的是助理。他获得布朗大学(Brown University)商业经济学和历史学学士学位和斯坦福大学商学院(Stanford University Graduate School of Business)的工商学硕士学位。他是Parasole Restaurant Holdings的董事。他在明尼阿波里斯市的圣保罗地区拥有几家餐厅,除此之外还有许多牛排餐厅。
David B. Roberts has served as Lemaitre Vascular, Inc. President since 2007 and as a member of Lemaitre Vascular, Inc. Board of Directors since 2001. Mr. Roberts joined Lemaitre Vascular, Inc. in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000, which position he held until 2007. Mr. Roberts received a Bachelor of Arts in Business Economics and History from Brown University and a Master of Business Administration from the Stanford University Graduate School of Business. Mr. Roberts is a director of Anteris Technologies (Nasdaq: AVR) where he serves as chair of the audit committee. He is also a director of Lexington Medical, Inc. and of Parasole Restaurant Holdings, Inc.
Joseph P. Pellegrino, Jr.

Joseph P. Pellegrino, Jr.,从2003年到2004年,他担任Affordable Luxuries公司(Affordable Luxuries公司是一个直接营销公司。2005年1月,根据美国破产法第七章该公司在马萨诸塞州的美国破产法院自愿申请清算。)的临时首席执行官。从1997年到2003年他在Zoots公司(Zoots公司是一个消费者服务公司由Staples的创办人创办。)任职。最近他担任高级副总裁负责运营。之前,他创建并转售一个地区性购物商场式专业零售公司。他还曾担任雷曼兄弟(Lehman Brothers)合并和收购集团的投资银行分析师。他获得一封哈佛大学(Harvard College)经济学学士学位和哈佛商学院(Harvard Business School)的工商管理硕士学位。


Joseph P. Pellegrino, Jr. served as Lemaitre Vascular, Inc. Chief Financial Officer from July 2007 to March 2025 and has served as a member of Lemaitre Vascular, Inc. Board of Directors since October 2016. Mr. Pellegrino joined Lemaitre Vascular, Inc. as Executive Vice President, Finance, in 2005. From 1997 to 2003, Mr. Pellegrino worked at Zoots, Inc., a consumer services company founded by the founders of Staples, Inc., where most recently he served as senior vice president of operations. Previously, Mr. Pellegrino built and sold a regional mall based specialty retailing company. Mr. Pellegrino has also served as an investment banking analyst at Lehman Brothers as part of their mergers and acquisitions group. Mr. Pellegrino became a director of Precision Optics Corporation, Inc., a designer and manufacturer of advanced optical instruments for the medical, defense, and aerospace industries, in 2025 and chairs their audit committee. Mr. Pellegrino received a Bachelor of Arts in Economics from Harvard College and a Master of Business Administration from the Harvard Business School.
Joseph P. Pellegrino, Jr.,从2003年到2004年,他担任Affordable Luxuries公司(Affordable Luxuries公司是一个直接营销公司。2005年1月,根据美国破产法第七章该公司在马萨诸塞州的美国破产法院自愿申请清算。)的临时首席执行官。从1997年到2003年他在Zoots公司(Zoots公司是一个消费者服务公司由Staples的创办人创办。)任职。最近他担任高级副总裁负责运营。之前,他创建并转售一个地区性购物商场式专业零售公司。他还曾担任雷曼兄弟(Lehman Brothers)合并和收购集团的投资银行分析师。他获得一封哈佛大学(Harvard College)经济学学士学位和哈佛商学院(Harvard Business School)的工商管理硕士学位。
Joseph P. Pellegrino, Jr. served as Lemaitre Vascular, Inc. Chief Financial Officer from July 2007 to March 2025 and has served as a member of Lemaitre Vascular, Inc. Board of Directors since October 2016. Mr. Pellegrino joined Lemaitre Vascular, Inc. as Executive Vice President, Finance, in 2005. From 1997 to 2003, Mr. Pellegrino worked at Zoots, Inc., a consumer services company founded by the founders of Staples, Inc., where most recently he served as senior vice president of operations. Previously, Mr. Pellegrino built and sold a regional mall based specialty retailing company. Mr. Pellegrino has also served as an investment banking analyst at Lehman Brothers as part of their mergers and acquisitions group. Mr. Pellegrino became a director of Precision Optics Corporation, Inc., a designer and manufacturer of advanced optical instruments for the medical, defense, and aerospace industries, in 2025 and chairs their audit committee. Mr. Pellegrino received a Bachelor of Arts in Economics from Harvard College and a Master of Business Administration from the Harvard Business School.
Lawrence J. Jasinski

Lawrence J. Jasinski,自2003年以来他成为我们的董事会成员。他担任埃尔格医学技术公司(Argo Medical Technologies公司创造了第一外骨骼技术并使其商业化,使瘫痪的人再走路的能力)首席执行官。从2005年到2012年,他Soteira公司(Soteira公司提供产品治疗个人椎体压缩性骨折。)的总裁兼首席执行官。从2000年到2005年,他Cortek公司(Cortek公司开发了新一代治疗椎间盘退变性疾病。)总裁兼首席执行官。从1985年到2000年他在波士顿科技公司(Boston Scientific Corporation)。从1998年到2000年他担任波士顿科技公司(Boston Scientific Corporation)的副总裁负责全球营销。他从普罗维登斯学院(Providence College)获得市场营销学士学位和布里奇波特大学(the University of Bridgeport)的工商管理硕士学位。


Lawrence J. Jasinski has served as a member of Lemaitre Vascular, Inc. Board of Directors since 2003. Mr. Jasinski is the chief executive officer, and a director, of MedRhythms Inc., a private company focused on rhythmic auditory stimulation of the brain. Previously, Mr. Jasinski served as the chief executive officer, and a director, of Lifeward Inc. (formerly ReWalk Robotics Ltd.) (Nasdaq: LFWD), a medical device company that designs and develops powered solutions providing gait training and mobility for lower limb disabilities, from 2012 to 2025. From 2005 until 2012, he was president and chief executive officer of Soteira, Inc., which offered products that treated individuals with vertebral compression fractures. From 2000 to 2005, he was president and chief executive officer of Cortek, Inc., which developed next generation treatments for degenerative disc disease. From 1985 to 2000, Mr. Jasinski worked at Boston Scientific Corporation and served as its vice president of global marketing for its vascular division from 1998 to 2000. Mr. Jasinski received a Bachelor of Science in Marketing from Providence College and a Master of Business Administration from the University of Bridgeport. Mr. Jasinski is also a member of the board of directors for Massachusetts Bay Lines, which offers commuter services and other commercial vessel services in the Boston Harbor and Islands.
Lawrence J. Jasinski,自2003年以来他成为我们的董事会成员。他担任埃尔格医学技术公司(Argo Medical Technologies公司创造了第一外骨骼技术并使其商业化,使瘫痪的人再走路的能力)首席执行官。从2005年到2012年,他Soteira公司(Soteira公司提供产品治疗个人椎体压缩性骨折。)的总裁兼首席执行官。从2000年到2005年,他Cortek公司(Cortek公司开发了新一代治疗椎间盘退变性疾病。)总裁兼首席执行官。从1985年到2000年他在波士顿科技公司(Boston Scientific Corporation)。从1998年到2000年他担任波士顿科技公司(Boston Scientific Corporation)的副总裁负责全球营销。他从普罗维登斯学院(Providence College)获得市场营销学士学位和布里奇波特大学(the University of Bridgeport)的工商管理硕士学位。
Lawrence J. Jasinski has served as a member of Lemaitre Vascular, Inc. Board of Directors since 2003. Mr. Jasinski is the chief executive officer, and a director, of MedRhythms Inc., a private company focused on rhythmic auditory stimulation of the brain. Previously, Mr. Jasinski served as the chief executive officer, and a director, of Lifeward Inc. (formerly ReWalk Robotics Ltd.) (Nasdaq: LFWD), a medical device company that designs and develops powered solutions providing gait training and mobility for lower limb disabilities, from 2012 to 2025. From 2005 until 2012, he was president and chief executive officer of Soteira, Inc., which offered products that treated individuals with vertebral compression fractures. From 2000 to 2005, he was president and chief executive officer of Cortek, Inc., which developed next generation treatments for degenerative disc disease. From 1985 to 2000, Mr. Jasinski worked at Boston Scientific Corporation and served as its vice president of global marketing for its vascular division from 1998 to 2000. Mr. Jasinski received a Bachelor of Science in Marketing from Providence College and a Master of Business Administration from the University of Bridgeport. Mr. Jasinski is also a member of the board of directors for Massachusetts Bay Lines, which offers commuter services and other commercial vessel services in the Boston Harbor and Islands.
John J. O'Connor

John J. O'Connor自2008年以来,一直担任Lemaitre Vascular, Inc.董事会成员。在2006年11月退休之前,O'Connor先生于1982年至2006年11月担任独立公共会计师事务所PricewaterhouseCoopers LLP的合伙人,最近于2002年6月至2006年11月担任服务副主席。O'Connor先生于2000年9月至2002年6月担任普华永道美国审计业务负责人,并于1995年至2000年9月担任波士顿办事处的管理合伙人。他是mTuitive, Inc.的董事,mTuitive, Inc.开发了医疗保健捕获和天气报告软件,供专业人员、制造服务公司Segue Manufacturing Services,LLC、提供连续交易监测解决方案和High Street Partners 临床数据的公司Oversight Systems,Inc.使用,一家全球咨询公司。在过去五年中,O'Connor先生还担任Aspect Medical Systems,Inc.的董事,Aspect Medical Systems,Inc.是一家被Covidien plc收购的上市大脑监测设备公司。2009年11月和企业治理提供商Open P,Inc.,风险与合规管理解决方案,2010年10月被IBM收购。O'Connor先生毕业于萨福克大学,曾就读于哈佛商学院的专业服务公司领导力项目和达特茅斯学院阿莫斯塔克学院的EMBA项目。


John J. O'Connor has served as a member of Lemaitre Vascular, Inc. Board of Directors since 2008. Prior to his retirement in December 2006, Mr. O'Connor was a partner at PricewaterhouseCoopers LLP, an independent public accounting firm, from 1982 to December 2006, most recently serving as vice chairman of services from June 2002 to November 2006. Mr. O'Connor served as the leader of the U.S. audit practice at PricewaterhouseCoopers from September 2000 to June 2002, and served as the Managing Partner of the firm's Boston office from 1995 to September 2000. He is a director of mTuitive, Inc., a developer of clinical data capture and synoptic reporting software for use by healthcare professionals; Health Data Analytics, Inc., a healthcare analytics company; Corvent Medical, Inc., a medical device company; and Almond Fintech, a digital payments company. He previously served on the board of Aspect Medical Systems and Abt Associates. Mr. O'Connor is a graduate of Suffolk University and has attended the Harvard Business School's Leadership in Professional Service Firms program and the executive Master of Business Administration program at the Amos Tuck School at Dartmouth College.
John J. O'Connor自2008年以来,一直担任Lemaitre Vascular, Inc.董事会成员。在2006年11月退休之前,O'Connor先生于1982年至2006年11月担任独立公共会计师事务所PricewaterhouseCoopers LLP的合伙人,最近于2002年6月至2006年11月担任服务副主席。O'Connor先生于2000年9月至2002年6月担任普华永道美国审计业务负责人,并于1995年至2000年9月担任波士顿办事处的管理合伙人。他是mTuitive, Inc.的董事,mTuitive, Inc.开发了医疗保健捕获和天气报告软件,供专业人员、制造服务公司Segue Manufacturing Services,LLC、提供连续交易监测解决方案和High Street Partners 临床数据的公司Oversight Systems,Inc.使用,一家全球咨询公司。在过去五年中,O'Connor先生还担任Aspect Medical Systems,Inc.的董事,Aspect Medical Systems,Inc.是一家被Covidien plc收购的上市大脑监测设备公司。2009年11月和企业治理提供商Open P,Inc.,风险与合规管理解决方案,2010年10月被IBM收购。O'Connor先生毕业于萨福克大学,曾就读于哈佛商学院的专业服务公司领导力项目和达特茅斯学院阿莫斯塔克学院的EMBA项目。
John J. O'Connor has served as a member of Lemaitre Vascular, Inc. Board of Directors since 2008. Prior to his retirement in December 2006, Mr. O'Connor was a partner at PricewaterhouseCoopers LLP, an independent public accounting firm, from 1982 to December 2006, most recently serving as vice chairman of services from June 2002 to November 2006. Mr. O'Connor served as the leader of the U.S. audit practice at PricewaterhouseCoopers from September 2000 to June 2002, and served as the Managing Partner of the firm's Boston office from 1995 to September 2000. He is a director of mTuitive, Inc., a developer of clinical data capture and synoptic reporting software for use by healthcare professionals; Health Data Analytics, Inc., a healthcare analytics company; Corvent Medical, Inc., a medical device company; and Almond Fintech, a digital payments company. He previously served on the board of Aspect Medical Systems and Abt Associates. Mr. O'Connor is a graduate of Suffolk University and has attended the Harvard Business School's Leadership in Professional Service Firms program and the executive Master of Business Administration program at the Amos Tuck School at Dartmouth College.
John A. Roush

John A. Roush,自2014年4月起,他成为我们的董事会成员。自2010年起,他担任首席执行官职务并成为GSI Group公司(GSI Group公司是应用于医疗、工业、科学和微电子市场的精密光学组件和子系统设备制造供应商。)董事会成员。加入GSI Group 公司之前,他是一个公司官员,担任12年的珀金埃尔默公司(PerkinElmer是为诊断、研究、环境、安全、工业和实验室服务市场提供技术和服务的供应商。)的高级领导职位。自2009年起,他一直担任珀金埃尔默公司(PerkinElmer)的总裁负责环境健康业务。从2004年到2009年,他负责珀金埃尔默公司(PerkinElmer)光电业务部,为生物医学和工业制造商供应专业光学产品。从1999年到2004年,他曾在光电业务部担任过许多综合管理职务。加入珀金埃尔默公司(PerkinElmer)之前,他曾担任过外装海运联合公司(Outboard Marine Corporation)和AlliedSignal,Inc.公司的管理职位,现在他在霍尼韦尔国际(Honeywell International),麦肯锡公司( McKinsey & Company Inc.)和通用电气(General Electric)担任管理职位。他获得塔夫茨大学(Tufts University)的电气工程学士学位和哈佛商学院(the Harvard Business School)工商管理硕士学位。


John A. Roush has served as a member of Lemaitre Vascular, Inc. Board of Directors since 2014. Mr. Roush serves as chief executive officer and a member of the board of directors of Pine Environmental LLC, a privately held company, which provides equipment and services to the environmental testing industry. He also serves as a board director and member of the compensation committee and nominating & corporate governance committee for Advanced Energy Industries, Inc. (Nasdaq: AEIS). Mr. Roush also serves as a board director for Targan, a privately held company that is developing vaccine delivery technology for animal health markets. From 2018 to 2024, Mr. Roush served as an executive director of ACON Investments, LLC. In this capacity, he assisted that firm in making private equity investments, and he served on the boards of directors of several ACON controlled companies. Prior to his involvement with ACON Investments, Mr. Roush served as chief executive officer and a member of the board of directors of Novanta Inc., a global supplier of precision photonic components and subsystems to original equipment manufacturers (OEMs) in the medical, industrial, scientific, and microelectronics markets, from 2010 to 2016. Prior to joining Novanta Inc., he was a corporate officer and served in several senior leadership positions for twelve years with PerkinElmer, Inc., a provider of technology and services to the diagnostics, research, environmental, safety and security, industrial, and laboratory services markets. Prior to joining PerkinElmer, Mr. Roush held management positions with Outboard Marine Corporation; AlliedSignal, Inc., now Honeywell International; McKinsey & Company Inc.; and General Electric. Mr. Roush received a Bachelor of Science in Electrical Engineering from Tufts University and a Master of Business Administration from the Harvard Business School.
John A. Roush,自2014年4月起,他成为我们的董事会成员。自2010年起,他担任首席执行官职务并成为GSI Group公司(GSI Group公司是应用于医疗、工业、科学和微电子市场的精密光学组件和子系统设备制造供应商。)董事会成员。加入GSI Group 公司之前,他是一个公司官员,担任12年的珀金埃尔默公司(PerkinElmer是为诊断、研究、环境、安全、工业和实验室服务市场提供技术和服务的供应商。)的高级领导职位。自2009年起,他一直担任珀金埃尔默公司(PerkinElmer)的总裁负责环境健康业务。从2004年到2009年,他负责珀金埃尔默公司(PerkinElmer)光电业务部,为生物医学和工业制造商供应专业光学产品。从1999年到2004年,他曾在光电业务部担任过许多综合管理职务。加入珀金埃尔默公司(PerkinElmer)之前,他曾担任过外装海运联合公司(Outboard Marine Corporation)和AlliedSignal,Inc.公司的管理职位,现在他在霍尼韦尔国际(Honeywell International),麦肯锡公司( McKinsey & Company Inc.)和通用电气(General Electric)担任管理职位。他获得塔夫茨大学(Tufts University)的电气工程学士学位和哈佛商学院(the Harvard Business School)工商管理硕士学位。
John A. Roush has served as a member of Lemaitre Vascular, Inc. Board of Directors since 2014. Mr. Roush serves as chief executive officer and a member of the board of directors of Pine Environmental LLC, a privately held company, which provides equipment and services to the environmental testing industry. He also serves as a board director and member of the compensation committee and nominating & corporate governance committee for Advanced Energy Industries, Inc. (Nasdaq: AEIS). Mr. Roush also serves as a board director for Targan, a privately held company that is developing vaccine delivery technology for animal health markets. From 2018 to 2024, Mr. Roush served as an executive director of ACON Investments, LLC. In this capacity, he assisted that firm in making private equity investments, and he served on the boards of directors of several ACON controlled companies. Prior to his involvement with ACON Investments, Mr. Roush served as chief executive officer and a member of the board of directors of Novanta Inc., a global supplier of precision photonic components and subsystems to original equipment manufacturers (OEMs) in the medical, industrial, scientific, and microelectronics markets, from 2010 to 2016. Prior to joining Novanta Inc., he was a corporate officer and served in several senior leadership positions for twelve years with PerkinElmer, Inc., a provider of technology and services to the diagnostics, research, environmental, safety and security, industrial, and laboratory services markets. Prior to joining PerkinElmer, Mr. Roush held management positions with Outboard Marine Corporation; AlliedSignal, Inc., now Honeywell International; McKinsey & Company Inc.; and General Electric. Mr. Roush received a Bachelor of Science in Electrical Engineering from Tufts University and a Master of Business Administration from the Harvard Business School.

高管简历

中英对照 |  中文 |  英文
Dorian LeBlanc

Dorian Leblanc自2016年11月起担任Lumiradx的副总裁,并自2020年8月起担任Lumiradx的全球业务。在加入Lumiradx之前,勒布朗先生曾在Alere担任过多个职位,包括从2013年3月至2015年11月担任传染病全球业务部财务副总裁,以及从2012年5月至2015年3月担任亚太地区财务和业务发展副总裁。从2005年7月到2007年11月,勒布朗先生担任Camden National Corporation财务副总裁。2003年11月至2005年7月,勒布朗先生担任Omnicom集团下属公司Pierce的财务主管。勒布朗先生在鲍登学院获得经济学学士学位,在东北大学获得会计学硕士学位和工商管理硕士学位。勒布朗先生是缅因州注册会计师。


Dorian LeBlanc has served as LumiraDx's Chief Financial Officer since November 2016 and has also served as the Vice President, Global Operations since August 2020. Prior to joining LumiraDx, Mr. LeBlanc held several positions with Alere, including as Vice President of Finance, Infectious Disease Global Business Unit from March 2013 to November 2015 and as Vice President Finance and Business Development for Asia Pacific from May 2012 to March 2015. From July 2005 to November 2007 Mr. LeBlanc served as Vice President, Finance at Camden National Corporation. From November 2003 to July 2005 Mr. LeBlanc served as controller for Pierce, a company in the Omnicom group. Mr. LeBlanc received a B.A. in economics from Bowdoin College, and a M.A. in accounting and a M.B.A. from Northeastern University. Mr. LeBlanc is a licensed Certified Public Accountant in the State of Maine.
Dorian Leblanc自2016年11月起担任Lumiradx的副总裁,并自2020年8月起担任Lumiradx的全球业务。在加入Lumiradx之前,勒布朗先生曾在Alere担任过多个职位,包括从2013年3月至2015年11月担任传染病全球业务部财务副总裁,以及从2012年5月至2015年3月担任亚太地区财务和业务发展副总裁。从2005年7月到2007年11月,勒布朗先生担任Camden National Corporation财务副总裁。2003年11月至2005年7月,勒布朗先生担任Omnicom集团下属公司Pierce的财务主管。勒布朗先生在鲍登学院获得经济学学士学位,在东北大学获得会计学硕士学位和工商管理硕士学位。勒布朗先生是缅因州注册会计师。
Dorian LeBlanc has served as LumiraDx's Chief Financial Officer since November 2016 and has also served as the Vice President, Global Operations since August 2020. Prior to joining LumiraDx, Mr. LeBlanc held several positions with Alere, including as Vice President of Finance, Infectious Disease Global Business Unit from March 2013 to November 2015 and as Vice President Finance and Business Development for Asia Pacific from May 2012 to March 2015. From July 2005 to November 2007 Mr. LeBlanc served as Vice President, Finance at Camden National Corporation. From November 2003 to July 2005 Mr. LeBlanc served as controller for Pierce, a company in the Omnicom group. Mr. LeBlanc received a B.A. in economics from Bowdoin College, and a M.A. in accounting and a M.B.A. from Northeastern University. Mr. LeBlanc is a licensed Certified Public Accountant in the State of Maine.
Dorian LeBlanc

Dorian LeBlanc自2025年3月起担任Lemaitre Vascular, Inc.首席财务官。勒布朗先生从下一代即时诊断公司LumiraDx有限公司(已被罗氏收购)加入勒梅特微管医疗,公司,最近一次自2016年11月起担任首席财务官,并于2020年8月被任命为全球运营副总裁,随后于2023年11月被任命为首席运营官。在加入LumiraDx之前,LeBlanc先生曾于2007年至2015年在Alere Inc.担任多个职务,包括2013年至2015年担任传染病全球业务部财务副总裁,以及2012年至2015年担任亚太区财务和业务发展副总裁。2005年至2007年,LeBlanc先生在Camden National Corporation担任财务副总裁。2003年至2005年,勒布朗先生担任宏盟集团旗下公司Pierce的财务总监。勒布朗先生获得鲍登学院经济学文学士学位,东北大学会计学理学硕士和工商管理硕士学位。勒布朗先生是缅因州的持牌注册会计师。


Dorian LeBlanc has served as Lemaitre Vascular, Inc. Chief Financial Officer since March 2025. Mr. LeBlanc joined Lemaitre Vascular, Inc. from LumiraDx Limited (acquired by Roche), a next generation point of care diagnostic company, where he most recently served as chief financial officer since November 2016, and was appointed vice president, global operations in August 2020, and subsequently appointed chief operating officer in November 2023. Prior to joining LumiraDx, Mr. LeBlanc held several positions with Alere Inc. from 2007 to 2015, including vice president of finance, infectious disease global business unit, from 2013 to 2015, and vice president, finance and business development for Asia Pacific from 2012 to 2015. From 2005 to 2007, Mr. LeBlanc served as vice president, finance, at Camden National Corporation. From 2003 to 2005, Mr. LeBlanc served as controller for Pierce, a company in the Omnicom group. Mr. LeBlanc received a Bachelor of Arts in Economics from Bowdoin College, and a Master of Science in accounting and a Master of Business Administration from Northeastern University. Mr. LeBlanc is a licensed Certified Public Accountant in the State of Maine.
Dorian LeBlanc自2025年3月起担任Lemaitre Vascular, Inc.首席财务官。勒布朗先生从下一代即时诊断公司LumiraDx有限公司(已被罗氏收购)加入勒梅特微管医疗,公司,最近一次自2016年11月起担任首席财务官,并于2020年8月被任命为全球运营副总裁,随后于2023年11月被任命为首席运营官。在加入LumiraDx之前,LeBlanc先生曾于2007年至2015年在Alere Inc.担任多个职务,包括2013年至2015年担任传染病全球业务部财务副总裁,以及2012年至2015年担任亚太区财务和业务发展副总裁。2005年至2007年,LeBlanc先生在Camden National Corporation担任财务副总裁。2003年至2005年,勒布朗先生担任宏盟集团旗下公司Pierce的财务总监。勒布朗先生获得鲍登学院经济学文学士学位,东北大学会计学理学硕士和工商管理硕士学位。勒布朗先生是缅因州的持牌注册会计师。
Dorian LeBlanc has served as Lemaitre Vascular, Inc. Chief Financial Officer since March 2025. Mr. LeBlanc joined Lemaitre Vascular, Inc. from LumiraDx Limited (acquired by Roche), a next generation point of care diagnostic company, where he most recently served as chief financial officer since November 2016, and was appointed vice president, global operations in August 2020, and subsequently appointed chief operating officer in November 2023. Prior to joining LumiraDx, Mr. LeBlanc held several positions with Alere Inc. from 2007 to 2015, including vice president of finance, infectious disease global business unit, from 2013 to 2015, and vice president, finance and business development for Asia Pacific from 2012 to 2015. From 2005 to 2007, Mr. LeBlanc served as vice president, finance, at Camden National Corporation. From 2003 to 2005, Mr. LeBlanc served as controller for Pierce, a company in the Omnicom group. Mr. LeBlanc received a Bachelor of Arts in Economics from Bowdoin College, and a Master of Science in accounting and a Master of Business Administration from Northeastern University. Mr. LeBlanc is a licensed Certified Public Accountant in the State of Maine.
George W. LeMaitre

George W. LeMaitre,自1992年起他曾担任首席执行官并成为董事会成员。自2004年起他担任主席。之前,他曾在雷曼兄弟(Lehman Brothers)担任投资银行分析师,McCown De Leeuw公司(McCown De Leeuw公司是融资合并公司。)担任助理,康涅狄格国家银行(Connecticut National Bank)担任信贷分析师。他获得斯坦福大学(Stanford University)的历史学学士学位和斯坦福大学商学院(the Stanford University Graduate School of Business)的工商管理硕士学位。


George W. LeMaitre has served as Lemaitre Vascular, Inc. Chief Executive Officer and as a member of Lemaitre Vascular, Inc. Board of Directors since 1992, serving as Lemaitre Vascular, Inc. Chairman since 2004. Previously, Mr. LeMaitre was an investment banking analyst at Lehman Brothers, an associate at the leveraged buyout firm McCown De Leeuw, and a credit analyst for Connecticut National Bank. Mr. LeMaitre received a Bachelor of Arts in History from Stanford University and a Master of Business Administration from the Stanford University Graduate School of Business.
George W. LeMaitre,自1992年起他曾担任首席执行官并成为董事会成员。自2004年起他担任主席。之前,他曾在雷曼兄弟(Lehman Brothers)担任投资银行分析师,McCown De Leeuw公司(McCown De Leeuw公司是融资合并公司。)担任助理,康涅狄格国家银行(Connecticut National Bank)担任信贷分析师。他获得斯坦福大学(Stanford University)的历史学学士学位和斯坦福大学商学院(the Stanford University Graduate School of Business)的工商管理硕士学位。
George W. LeMaitre has served as Lemaitre Vascular, Inc. Chief Executive Officer and as a member of Lemaitre Vascular, Inc. Board of Directors since 1992, serving as Lemaitre Vascular, Inc. Chairman since 2004. Previously, Mr. LeMaitre was an investment banking analyst at Lehman Brothers, an associate at the leveraged buyout firm McCown De Leeuw, and a credit analyst for Connecticut National Bank. Mr. LeMaitre received a Bachelor of Arts in History from Stanford University and a Master of Business Administration from the Stanford University Graduate School of Business.
Trent G. Kamke

Trent G. Kamke,自2005年以来他担任我们的高级副总裁负责运营。他于1997年加入我们担任项目质量经理。从1999年到2005年他担任副总裁负责运营。在1997年加入我们公司之前,他在美国血液技术公司(Haemonetics Corporation 是设计、制造商和销售自动血液处理设备的公司。)任职,他获得科尔比学院(Colby College)的物理学学士学位和泰尔达特茅斯大学(Dartmouth College)的工程学院教育学硕士学位。


Trent G. Kamke has served as Lemaitre Vascular, Inc. Senior Vice President, Operations, since 2005. Mr. Kamke joined Lemaitre Vascular, Inc. in 1997 as Quality Assurance Manager. From 1999 to 2005, Mr. Kamke served as Lemaitre Vascular, Inc. Vice President, Operations. Prior to joining Lemaitre Vascular, Inc. in 1997, Mr. Kamke was employed by Haemonetics Corporation, which designs, manufactures, and markets automated blood processing equipment. Mr. Kamke received a Bachelor of Arts in Physics from Colby College and a Bachelor of Engineering from the Thayer School of Engineering at Dartmouth College.
Trent G. Kamke,自2005年以来他担任我们的高级副总裁负责运营。他于1997年加入我们担任项目质量经理。从1999年到2005年他担任副总裁负责运营。在1997年加入我们公司之前,他在美国血液技术公司(Haemonetics Corporation 是设计、制造商和销售自动血液处理设备的公司。)任职,他获得科尔比学院(Colby College)的物理学学士学位和泰尔达特茅斯大学(Dartmouth College)的工程学院教育学硕士学位。
Trent G. Kamke has served as Lemaitre Vascular, Inc. Senior Vice President, Operations, since 2005. Mr. Kamke joined Lemaitre Vascular, Inc. in 1997 as Quality Assurance Manager. From 1999 to 2005, Mr. Kamke served as Lemaitre Vascular, Inc. Vice President, Operations. Prior to joining Lemaitre Vascular, Inc. in 1997, Mr. Kamke was employed by Haemonetics Corporation, which designs, manufactures, and markets automated blood processing equipment. Mr. Kamke received a Bachelor of Arts in Physics from Colby College and a Bachelor of Engineering from the Thayer School of Engineering at Dartmouth College.